Arcus Biosciences (RCUS) Citigroup’s Biopharma Back to School Summit 2026 summary

Key data updates and clinical strategy

• Major data update planned for October, covering late-line, second-line, and frontline settings for casdatifan in renal cell carcinoma, with an investor event scheduled for October 20th.

• Late-line monotherapy data show improved progression-free survival (PFS) of 12–15 months versus 5.6 months for the comparator, with overall survival (OS) data to be presented for the first time; 28 months median follow-up expected.

• Second-line pivotal study (PEAK-1) combines casdatifan with cabozantinib; enrollment is progressing well and expected to complete by year-end, with data maturity at 20 months and benchmarks set against LITESPARK-011 and real-world populations.

• Frontline strategy involves combining casdatifan with ipilimumab and nivolumab (PEAK-20), with early data suggesting potential for improved disease control and tolerability compared to TKI-based regimens.

• Both pivotal studies (PEAK-1 and ARC-20) are expected to have similar timelines, with first data readouts anticipated in the first half of 2028.

Competitive positioning and market opportunity

• Casdatifan is designed to overcome pharmacokinetic limitations of belzutifan, offering dose-proportional and linear PK, and higher pharmacodynamic effect.

• Data suggest casdatifan maintains efficacy in patients with multiple prior TKI treatments, potentially outperforming belzutifan in these populations.

• The second-line market opportunity is estimated at $1.5–2 billion, while the frontline opportunity could exceed $4 billion, with frontline data expected to drive confidence in commercial potential.

• Casdatifan plus anti-PD-1 regimens may offer better tolerability and sustained efficacy compared to TKI combinations, with the potential to match or exceed current standards.

• The company is leveraging AI tools in drug discovery and design, focusing on areas where high-quality data inputs can accelerate progress.

Upcoming milestones and investor considerations

• October 20th investor event will provide new data across all lines of therapy, including OS and PFS updates, response rates, and safety profiles.

• PEAK-1 enrollment to complete by year-end, with ARC-20 initiation expected around the same time and rapid enrollment anticipated.

• Data from both pivotal studies are expected in a similar timeframe, with first readouts likely in the first half of 2028.

• The late-line monotherapy data have de-risked the pivotal studies, and the second-line setting is seen as the core value driver.

• Frontline data could significantly expand commercial opportunity and investor confidence.